The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...
The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...
Aug. 13, 2004 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., sent a letter yesterday to healthcare professionals that warns of the risk for serious and fatal arterial ...
September 26, 2006 — The US Food and Drug Administration (FDA) and Genentech, Inc, have notified healthcare professionals regarding safety labeling revisions for bevacizumab injection (Avastin) that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback